Please login to the form below

Not currently logged in

Nanobiotix strengthens US leadership team

Dr Mihail Obrocea and Noël Kurdi join the nanomedicine company

Nanobiotix Dr Mihail ObroceaFrench oncology specialist Nanobiotix has strengthened its US leadership team with the appointments of Dr Mihail Obrocea and Noël Kurdi.

Dr Obrocea (pictured right) joins Nanobiotix as head of US clinical development, bringing 20 years of clinical research leadership to the role.

Most recently, Dr Obrocea was AbbVie Biotherapeutics' project director and oncology clinical lead, overseeing a number of trials in oncology and hematology.

He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

Nanobiotix Noel KurdiMeanwhile, Kurdi (pictured left) becomes director of investor relations at Nanobiotix, moving from the Trout Group where she served as a senior associate.

Kurdi has previously worked in institutional equity sales and research at Brean Capital, and business development and investor relations at AIG Investments in New York.

7th October 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....